RC
KROS icon

Rangeley Capital’s Keros Therapeutics KROS Stock Holding History

Rangeley Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$601K Sell
54,400
-42,400
-44% -$655K 0.58% 43
2025
Q4 		$1.97M Sell
96,800
-161,819
-63% -$2.84M 1.64% 18
2025
Q3 		$4.09M Sell
258,619
-26,781
-9% -$396K 3.54% 8
2025
Q2 		$3.81M Sell
285,400
-122,834
-30% -$1.66M 4.55% 6
2025
Q1 		$4.16M Buy
+408,234
New +$4.74M 4.46% 6

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Rangeley Capital's KROS Position: Q1 2026 in Review

Rangeley Capital reduced its Keros Therapeutics (KROS) stake by 44% in Q1 2026, selling an estimated $655K and leaving 54,400 shares worth $601K. The position accounts for 0.58% of the portfolio, ranked #43.

Rangeley Capital first reported a position in KROS in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.16M in Q1 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Rangeley Capital held 54,400 shares of Keros Therapeutics worth $601K as of Q1 2026.
  • Rangeley Capital sold 42,400 Keros Therapeutics shares in Q1 2026, an estimated $655K.
  • Keros Therapeutics made up 0.58% of Rangeley Capital's portfolio in Q1 2026, its #43 holding.
  • Rangeley Capital first reported a position in Keros Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Rangeley Capital's Keros Therapeutics position peaked at $4.16M in Q1 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.